New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
March 7, 2013
10:00 EDTAWK, KWK, UNFI, SCTY, AGN, MCY, VITC, SD, GRP, FMS, DGI, DDAIF, DVA, BIG, CWHOn The Fly: Analyst Downgrade Summary
Today's noteworthy downgrades include: American Water (AWK) downgraded to Neutral from Buy at Citigroup... Big Lots (BIG) downgraded to Hold from Buy at Canaccord... DaVita (DVA) downgraded to Hold from Buy at Deutsche Bank... Daimler AG (DDAIF) downgraded to Neutral from Buy at Citigroup... DigitalGlobe (DGI) downgraded to Hold from Buy at Benchmark Co... Fresenius Medical (FMS) downgraded to Sector Perform from Outperform at RBC Capital... Granite Real Estate (GRP) downgraded to Sector Perform from Outperform at RBC Capital... Lincoln Educational (LINC) downgraded to Underperform from Market Perform at BMO Capital... SandRidge Energy (SD) downgraded to Underperform from Market Perform at BMO Capital... Vitacost.com (VITC) downgraded to Sell from Neutral at Roth Capital... Mercury General (MCY) downgraded to Neutral from Outperform at Macquarie... Allergan (AGN) downgraded to Neutral from Buy at Buckingham... SolarCity (SCTY) downgraded to Hold from Buy at Needham... United Natural Foods (UNFI) downgraded to Hold from Buy at Argus... Quicksilver Resources (KWK) downgraded to Hold from Buy at MLV Equity... CommonWealth REIT (CWH) downgraded to Sell from Hold at Stifel Nicolaus.
News For AWK;BIG;DVA;DDAIF;DGI;FMS;GRP;SD;VITC;MCY;AGN;SCTY;UNFI;KWK;CWH From The Last 14 Days
Sign up for a free trial to see the rest of the stories you've been missing.
1 | 2 | 3 | 4 | all recent news | >>
October 9, 2014
16:21 EDTKWKQuicksilver Resources receives continued listing standards notice from NYSE
Subscribe for More Information
14:21 EDTAGNAllergan in good position to be patient given raised outlook, says BMO Capital
After speaking with Allergan's (AGN) CEO and CFO, BMO Capital believes the company is increasing its intrinsic value with its raised earnings guidance and that it is in a good position to be patient given that Valeant (VRX) most recent bid represents an 8% discount to Allergan's current share price. BMO said it is reviewing its forecasts for Allergan after the guidance increase, noting that it previously valued Allergan at $230 per share on a standalone basis. The firm maintains its Outperform rating on the stock.
12:28 EDTAGNAllergan price target raised to $230 from $210 at BTIG
BTIG said it expected Allergan to beat the consensus forecast for Q3 EPS, but not by as much as it did, and the firm did not expect the company to raise its future EPS outlook yet again. BTIG feels the stock's move higher indicates Valeant (VRX) or Actavis (ACT) would need to bid above $200 if they hope to buy the company. BTIG maintains its Buy rating on Allergan and raised its price target on the stock to $230 from $210.
11:14 EDTAGNAllergan raises outlook again as Valeant pursuit continues
Drug maker Allergan (AGN) this morning preannounced stronger than expected results and again raised its fiscal year profit guidance. The beat and raise results come after The Wall Street Journal reported on Tuesday that drug maker Valeant (VRX) and hedge fund Pershing Square intend to raise their previous bid for Allergan by $15 per share to about $191. Meanwhile, also on Tuesday, Reuters said that drug maker Actavis (ACT) plans to make a new merger offer to Allergan, and sources indicated to the news service that Allergan may be willing to consider an offer from Actavis if the bid is for more than $200 per share. WHAT'S NEW: Allergan estimated that its third quarter earnings per share would come in at $1.76-$1.78, versus analysts' consensus estimate of $1.48. The drug maker had previously provided Q3 EPS guidance of $1.44-$1.47. Allergan raised its fiscal 2014 EPS guidance to $6.20-$6.25 from $5.74-$5.80. Analysts' consensus estimate was $5.81. This is the fourth time that Allergan has raised its guidance this year. Allergan said that its markets have been strong around the world, while it is gaining market share in most categories. ANALYST REACTION: In a note to investors today, Wells Fargo analyst Larry Biegelsen wrote that, in the wake of Allergan's guidance increase, the company's price to earnings multiple could expand to 22x its estimated 2016 earnings, up from its current multiple of 19x. In addition to the raised guidance, a potential accretive acquisition by Allergan and the possibility that it will be acquired make such an increase in the multiple "quite possible," Biegelsen contended. He kept an Outperform rating on the stock. WHAT'S NOTABLE: Allergan has reportedly held advanced talks about acquiring another company in the sector, Salix (SLXP), although CNBC's David Faber on October 2 reported that the talks between the two companies about a merger had "cooled considerably." PRICE ACTION: In late morning trading, Allergan rose fractionally to $191.06 while Valeant slid 1.5% to $124.08.
10:00 EDTAGNOn The Fly: Analyst Initiation Summary
Subscribe for More Information
08:53 EDTSCTYSolarCity solar loans could be a game changer, says Roth Capital
Subscribe for More Information
08:50 EDTAGNAllergan shares have further upside, says Wells Fargo
Subscribe for More Information
07:59 EDTKWKCrestwood Equity Crestwood Midstream weakness overdone, says Wells Fargo
After Crestwood Equity Partners LP(CEQP) and Crestwood Midstream Partners LP(CMLP) underperformed their broader group over the past month, Wells Fargo thinks the underperformance was driven by Quicksilver Resource's (KWK) financial struggles, concerns regarding gas storage fundamentals as it impacts Tres Palacios, and a decline in crude prices driving reduced activity in the Bakken. The firm believes that these concerns are legitimate, but it does not view them as new and calls the weakness in the stocks overdone. It keeps a Market Perform rating on Crestwood Equity Partners and an Outperform rating on Crestwood Midstream Partners.
06:49 EDTAGNAllergan cites momentum from robust growth of worldwide markets
The company also cites increases in market share in most categories, many regulatory approvals for new products in the U.S. and internationally, and targeted investments to create and grow new products and new categories. Exceptional growth in EPS from the acceleration in sales but also in leveraging of sales and marketing expenditures. The benefits from Allergan’s previously announced restructuring program will be reflected in the Company’s actual results beginning in the fourth quarter of 2014 and continuing through 2015.
06:47 EDTAGNAllergan sees FY16 non-GAAP EPS $10.25
06:47 EDTAGNAllergan sees FY15 non-GAAP EPS $8.60, consensus $8.25
Subscribe for More Information
06:47 EDTAGNAllergan sees FY14 non-GAAP EPS $6.20-$6.25, consensus $5.81
Subscribe for More Information
06:46 EDTAGNAllergan raises Q3 EPS to $1.76-$1.78 from $1.44-$1.47, consensus $1.48
Expects Q3 product net sales to increase in excess of 17% in dollars compared to product net sales from 3Q13.
October 8, 2014
16:10 EDTAGNAllergan initiated with a Buy at Deutsche Bank
Subscribe for More Information
10:01 EDTSCTYSolarCity and Honda renew partnership to fund $50M in solar projects
Subscribe for More Information
08:42 EDTAGNSalix shares should be bought on weakness, says Sterne Agee
After Reuters yesterday afternoon reported that Actavis (ACT) plans to make a new merger approach to Allergan (AGN), Sterne Agee believes that Salix's standalone value is $162. The firm expects the shares to reach that level following approval of its Xifaxan IBS-D drug after the February 2015 PDUFA date.
08:11 EDTSCTYSolarCity launch of MyPower expected but details a positive, says BofA/Merrill
Subscribe for More Information
07:19 EDTAGNCBI to hold a conference
Subscribe for More Information
06:23 EDTAGNActavis more inclined to pursue Allergan over Salix, says Citigroup
Subscribe for More Information
06:02 EDTSCTYSolarCity adds financing option in move to expand
SolarCity introduced MyPower today, a solar financing option that combines the low upfront cost and immediate utility savings of a power purchase agreement with the benefits of ownership. SolarCity customers pay for their MyPower solar loan similar to the way they pay for a solar PPA—based on the energy the system produces from the sun—but they retain ownership of the solar panels. MyPower's unique structure creates America's most affordable solar loan—with a lower cost than PPAs in many locations. MyPower can allow customers to pay as much as 40% less for solar power than utility power, and unlike other loans, MyPower allows customers to prepay their entire balance or prepay a portion of their solar loan to lower their monthly payments at any time, with no fees or penalties. Starting today, SolarCity will offer MyPower to customers in Arizona, California, Colorado, Connecticut, Hawaii, Massachusetts, New York and New Jersey, and ultimately plans to expand the product beyond its existing service territory.
1 | 2 | 3 | 4 | all recent news | >>

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the theflyonthewall.com disclaimer & terms of use